Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) reduces infection-related mortality after allogeneic T-cell depleted BMT

Bone Marrow Transplant. 1991:7 Suppl 2:83.

Authors

T De Witte¹, A Gratwohl, N Van der Lely, A Bacigalupo, A C Stern, B Speck, A Schattenberg, C Nissen, E Gluckman, W E Fibbe

Affiliation

¹ University Hospital Nijmegen, The Netherlands.

PMID: 1908729

No abstract available

Publication types

Clinical Trial
Multicenter Study
Randomized Controlled Trial

MeSH terms

Bone Marrow Transplantation / adverse effects*
Double-Blind Method
Europe / epidemiology
Graft Survival / drug effects
Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
Hematopoiesis / drug effects
Humans
Immunologic Factors / pharmacology
Immunologic Factors / therapeutic use*
Infection Control*
Infections / etiology
Infections / mortality
Leukocyte Count / drug effects
Lymphocyte Depletion
Neutropenia / complications
Neutropenia / therapy
Prospective Studies
Recombinant Proteins / pharmacology
Recombinant Proteins / therapeutic use
T-Lymphocytes / immunology

Substances

Immunologic Factors
Recombinant Proteins
Granulocyte-Macrophage Colony-Stimulating Factor